{"id":"csii-insulin-lispro","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Lipodystrophy"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin lispro is a recombinant human insulin analog with a rapid onset of action (10-15 minutes) and shorter duration compared to regular human insulin. When administered via continuous subcutaneous insulin infusion (CSII), it mimics the body's natural postprandial insulin secretion by binding to insulin receptors on muscle and adipose tissue, promoting glucose uptake and storage while suppressing hepatic glucose production.","oneSentence":"Insulin lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:44:01.721Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus (when insulin therapy is required)"}]},"trialDetails":[{"nctId":"NCT04276207","phase":"PHASE1","title":"A Study of LY900014 Versus Insulin Lispro (Humalog) on High Blood Sugar in Participants With Type 1 Diabetes Who Use Insulin Pumps","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-25","conditions":"Diabetes Mellitus, Type 1","enrollment":32},{"nctId":"NCT03830281","phase":"PHASE3","title":"A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-14","conditions":"Type 1 Diabetes Mellitus","enrollment":471},{"nctId":"NCT03760640","phase":"PHASE2","title":"A Study of LY900014 in a Medtronic Pump","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-18","conditions":"Type1 Diabetes Mellitus","enrollment":42},{"nctId":"NCT04161976","phase":"PHASE1","title":"A Study of LY900027 Given by Insulin Pump to Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-27","conditions":"Diabetes Mellitus, Type 1","enrollment":20},{"nctId":"NCT03465878","phase":"PHASE1","title":"A Study of LY900014 in Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-03-26","conditions":"Type 1 Diabetes Mellitus","enrollment":56},{"nctId":"NCT03433677","phase":"PHASE3","title":"A Study of LY900014 and Insulin Lispro With an External Continuous Subcutaneous Insulin Infusion System in Adult Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-02-21","conditions":"Diabetes Type 1","enrollment":49},{"nctId":"NCT03890003","phase":"NA","title":"A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-03-28","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT03849612","phase":"NA","title":"A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-21","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT03848767","phase":"NA","title":"A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus During Meal Challenges","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-02-20","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT01109316","phase":"PHASE3","title":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-04","conditions":"Diabetes Mellitus, Type 1","enrollment":132},{"nctId":"NCT01526733","phase":"PHASE4","title":"Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2011-12","conditions":"Type 1 Diabetes Mellitus","enrollment":25},{"nctId":"NCT03743285","phase":"NA","title":"A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes Mellitus (T1D)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2018-11-14","conditions":"Type 1 Diabetes Mellitus","enrollment":10},{"nctId":"NCT03662334","phase":"PHASE4","title":"A Study of Continuous Subcutaneous Insulin Infusion (CSII) Pump Function in Subjects With Type 1 Diabetes With Recombinant Human Hyaluronidase (rHuPH20)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-10-03","conditions":"Type 1 Diabetes Mellitus","enrollment":14},{"nctId":"NCT01848990","phase":"PHASE4","title":"CONSISTENT 1: Metabolic and Safety Outcomes of Hylenex Recombinant (Hyaluronidase Human Injection) Preadministered at CSII Infusion Site in Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Halozyme Therapeutics","startDate":"2013-03","conditions":"Type 1 Diabetes Mellitus","enrollment":456},{"nctId":"NCT03156361","phase":"PHASE2","title":"21 Day Comparison of Continuous Insulin Infusion Using HDV Insulin to Standard Insulin in Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Diasome Pharmaceuticals","startDate":"2017-05-18","conditions":"Type1 Diabetes Mellitus","enrollment":24},{"nctId":"NCT03563794","phase":"PHASE4","title":"Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2018-06-10","conditions":"T2DM","enrollment":400},{"nctId":"NCT03463564","phase":"PHASE4","title":"Insulin Pump vs Multiple Daily Injections of Insulin and Glyco-metabolic Control in Type 1 Diabetic Patients","status":"RECRUITING","sponsor":"University of Campania Luigi Vanvitelli","startDate":"2016-01","conditions":"Type 1 Diabetes Mellitus","enrollment":150},{"nctId":"NCT03367390","phase":"PHASE1","title":"A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2017-11-08","conditions":"Type1 Diabetes Mellitus","enrollment":30},{"nctId":"NCT00574405","phase":"NA","title":"Preservation of Pancreatic Beta Cell Function Through Insulin Pump Therapy","status":"COMPLETED","sponsor":"Arkansas Children's Hospital Research Institute","startDate":"2005-04","conditions":"Diabetes Mellitus","enrollment":24},{"nctId":"NCT00652288","phase":"PHASE1","title":"Evaluation of Pharmacokinetics and Pharmacodynamic Properties of Rapid-Acting Insulin Analogs","status":"COMPLETED","sponsor":"Yale University","startDate":"2007-04","conditions":"Diabetes Mellitus, Type I","enrollment":36},{"nctId":"NCT02603510","phase":"PHASE1","title":"Assessment of the Safety of SAR342434 and Humalog® When Administered as Continuous Subcutaneous Insulin Infusion","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-11","conditions":"Type 1 Diabetes Mellitus","enrollment":27},{"nctId":"NCT01776788","phase":"PHASE4","title":"Effect of Short-Term Intensive Insulin Sequential Exenatide Therapy in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2012-08","conditions":"Diabetes Mellitus, Type 2","enrollment":156},{"nctId":"NCT01474538","phase":"PHASE3","title":"Safety and Efficacy Study of Insulin Lispro Versus Insulin Aspart in Participants With Type 2 Diabetes on Insulin Pump Therapy","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Type 2 Diabetes Mellitus","enrollment":122},{"nctId":"NCT01134107","phase":"PHASE3","title":"Insulin Lispro 6 Days Versus Insulin Aspart 6 Days in Pump Use","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-11","conditions":"Diabetes Mellitus, Type 1","enrollment":133},{"nctId":"NCT00607087","phase":"PHASE4","title":"Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2008-01","conditions":"Diabetes Mellitus, Type 1","enrollment":289}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":64,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"CSII(insulin Lispro)","genericName":"CSII(insulin Lispro)","companyName":"The First Affiliated Hospital of Xiamen University","companyId":"the-first-affiliated-hospital-of-xiamen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin Lispro is a protein-based insulin receptor agonist used to treat various forms of diabetes, including Type 1 and Type 2 Diabetes Mellitus. It is classified as an agonist and is used in insulin pump therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}